CN101062021A - Diarrhea treating medical composition - Google Patents
Diarrhea treating medical composition Download PDFInfo
- Publication number
- CN101062021A CN101062021A CNA2007100178409A CN200710017840A CN101062021A CN 101062021 A CN101062021 A CN 101062021A CN A2007100178409 A CNA2007100178409 A CN A2007100178409A CN 200710017840 A CN200710017840 A CN 200710017840A CN 101062021 A CN101062021 A CN 101062021A
- Authority
- CN
- China
- Prior art keywords
- eugenol
- pharmaceutical composition
- polyvinylpolypyrrolidone
- present
- diarrhoea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010012735 Diarrhoea Diseases 0.000 title abstract description 50
- 239000000203 mixture Substances 0.000 title abstract description 13
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims abstract description 83
- 229960002217 eugenol Drugs 0.000 claims abstract description 42
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000005770 Eugenol Substances 0.000 claims abstract description 41
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000000725 suspension Substances 0.000 claims description 28
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 24
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 24
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 230000000741 diarrhetic effect Effects 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 238000005498 polishing Methods 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 35
- 230000000694 effects Effects 0.000 description 30
- 230000000968 intestinal effect Effects 0.000 description 11
- 239000003053 toxin Substances 0.000 description 11
- 231100000765 toxin Toxicity 0.000 description 11
- 108700012359 toxins Proteins 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 201000009840 acute diarrhea Diseases 0.000 description 7
- 238000001035 drying Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229910021647 smectite Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- -1 polyethylene pyrrole Polymers 0.000 description 4
- 208000004232 Enteritis Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 208000012873 acute gastroenteritis Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 244000061408 Eugenia caryophyllata Species 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 241001137327 Vireo Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 201000009868 osmotic diarrhea Diseases 0.000 description 1
- 208000028719 osmotic diarrheal disease Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 201000009881 secretory diarrhea Diseases 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicinal composition for treating loose bowel movement, which comprises eugenol 0. 05-5%, crosslinked povidone 20-80%, pharmaceutically acceptable adjunct 20-80%.
Description
Technical field
The present invention relates to field of medicaments, especially a kind of pharmaceutical composition of forming by eugenol and a kind of high molecular polymer polyvinylpolypyrrolidone (pvpp) that is used for the treatment of diarrhoea and condition of illness such as abdominal distention, stomachache and acute gastroenteritis.
Background technology
Diarrhoeal diseases (diarrhoea disease) is a kind of commonly encountered diseases, and frequently-occurring disease is by multiple cause of disease, and what multiple factor caused is one group of disease of main performance with diarrhoea.This disease is often followed symptoms such as abdominal distention, stomachache and acute gastroenteritis, and is very big to human health risk.World Health Organization (WHO) will suffer from diarrhoea to control and classify global strategy as.Investigation according to health organization shows that the diarrheal fatality rate is high, occupy the 4th of various diseases, is only second to after tumor, the heart, cerebrovascular, the diabetes.Along with the variation of global climate in recent years, annual increasing flood further aggravates diarrheal and grows and spread; Developing country is because the restriction of self sanitary installation and medical level, and diarrhoea is more obvious to the harm that the mankind cause, and wherein the child is acute one of the most serious colony that suffered from diarrhoea.According to statistics in 2002, in developing country, cause in the reason of death of child below 5 years old, diarrhoea occupies second (15%), is only second to acute respiratory infection (18%).Epidemiological study also illustrate 42% child's body weight gain stop or descending owing to diarrhoea reason cause.This common disease of acute diarrhea and the concern that child's threat is being caused whole world society.
During Epidemiological study diarrhoea is defined as: discharged the lax or water sample stool more than 3 times or 3 times in 24 hours, lax stool refers to that its form decides with the shape of container.Pediatrics are defined as for diarrheal: the flowability of stool, volume and the individual ordinary practice of defecation frequency and each are compared obvious increase.So-called acute diarrhea is meant that onset is hurried, just thorn and just amount is many, just matter is thin, has food debris or mucus, pus and blood, every day defecation frequency even more than 10 times, often with symptoms such as heating, stomachache, tenesmus, loss of appetite, nausea and vomiting.Can cause dehydration, electrolyte disturbance and metabolic acidosis when acute diarrhea is serious.
The acute diarrhea pathomechanism mainly is divided into four kinds of mechanism, that is: osmotic diarrhea, secretory diarrhea, exudative diarrhoea, the disorderly diarrhoea of intestinal motive force.
At present, treat the diarrheal medicine both at home and abroad and mainly be divided into three major types: antibiotic, microbial ecological agent, intestinal mucosa protection and astringing to arrest diarrhea agent.
1) gives birth to plain class medicine
Studies show that in recent years has only 30% needs of patients use antibiotic in the diarrhoea, generally be the crowd of bacillary dysentery, cholera, infant salmonella, various serious symptom, immunologic hypofunction.As stool band pus and blood, the infant below 12 years old, the symptom that heating suddenly, pale complexion, coolness of extremities, muscle are felt nervous appears, and the diarrhoea of special sufferer.Common medicine has: norfloxacin, berberine etc.
Along with the continuous development to biopathogen body and the research of diarrhoeal diseases mechanism, a large amount of clinical datas show that all after using the several years, curative effect progressively descends various antibiotic, make the multiple treatment of diseases that comprises diarrhoea become difficult.Especially the use of broad ectrum antibiotic has also produced the effect that destroys patient's normal intestinal flora, and secondary dysbacteriosis, superinfection are left over the future trouble that is difficult to recover to the patient easily.The antibiotic improper use, its side effect is possibly greater than therapeutical effect.The noninfectious diarrhea that causes for reasons such as improper diet, abrupt change of climate for example, antibiotic is without any effect.By the infectious diarrhea that escherichia coli cause, can stimulate antibacterial to discharge toxin after the use, symptoms such as hyperpyrexia, stomachache, hyperemesis may appear.Therefore, " not abuse of antibiotics " become a cardinal principle on the clinical treatment.Under such principle, the diarrhoea pharmaceutical market share that antibiotic occupies presents downward trend.
2) microbial ecological agent
Microbial ecological agent class medicine is to be purpose to foster normal intestinal flora, by the biological antagonist effect, suppresses pathogen growth, reaches the effect of kill pathogens indirectly.Be mainly used in diarrhoea that alteration of intestinal flora causes and by the excitation diarrhoea due to cold and the various stimulations.The common medicine of this class is: happy, the whole intestinal life of beautiful pearl intestinal, Birid Triple Viable, Medilac-Vita etc.
3) echo the medicine of astriction
This class medicine have extremely strong absorbability to virus, antibacterial and bacterial poison, makes it lose pathogenic effects.The dioctahedral smectite that the rich good fortune of modal medicine of this class such as France is produced.This medicine major side effects is to cause constipation, the auxiliary reparation that suffers for want of medical supplies and regulate humoral effect, and also import drugs costs an arm and a leg, and increases the weight of patient's medication burden.
Therefore, study and a kind ofly can protect intestinal, again can be extremely urgent to the medicine that noxious bacteria and toxin are removed.
Summary of the invention
Shortcomings such as the present invention is big for solving the side effect of existing diarrhoea drug intoxication, and price is high, and a kind of medicine that contains eugenol and high polymer polyvinylpolypyrrolidone is provided, be used for the treatment of diarrhoea and be particularly useful for the child and be grown up acute or subacute diarrhoea.The present invention not only can keep eugenol dispersing cold for relieving pain, antibiotic, the pharmacological action of pvpp absorbing toxin, protection intestinal mucosa, and can bring significant diarrhea effect for the compound recipe of forming.When the bacillary intestinal infection of treatment, do not need to cooperate antibacterials, toxic and side effects is little.
Technical solution of the present invention is: the present invention is a kind of treatment diarrheal pharmaceutical composition, and it comprises eugenol, polyvinylpolypyrrolidone and acceptable accessories.
Above-mentioned treatment diarrheal pharmaceutical composition, wherein the content of eugenol is: 0.05-5%, the content of PVPP is: 20-80%, the content of acceptable accessories is: 20-80%,
The content that preferred content is eugenol is: 0.2-2%, the content of PVPP is: 40-70%, the content of pharmaceutically acceptable adjuvant is: 28-58%.
Preferred content is that the content of eugenol is: 0.5-1.5%, the content of PVPP is: 50-60%, the content of acceptable accessories is: 38.5-48.5%.
Above-mentioned pharmaceutically acceptable adjuvant is selected from one or more in sodium chloride, mannitol, lactose, sucrose, sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium, 3%-5%pvp ethanol solution, sodium chloride, polyvinylpolypyrrolidone, microcrystalline Cellulose or the magnesium stearate.
Above-mentioned treatment diarrheal pharmaceutical composition can be made into dry suspension, suspension, powder, granule, tablet oral administration solid or liquid preparation.
When aforementioned pharmaceutical compositions was made dry suspension, suspension, eugenol was the eugenol that carries out enclose with beta-schardinger dextrin-.
Above-mentioned inclusion method adopts recrystallization method or polishing.
Eugenol is to be effective ingredient in the Myrtaceae Flos Caryophylli (Eugenia caryophyllata Thumb), eugenol (Eugenol), another name eugenol (Eugenic acid corophyllic acid), chemical name is (Phenol, 2-methoxy-4-(2-propenyl-).Eugenol is colourless or flaxen oily liquids, has intensive Flos Caryophylli gas and hot fragrance flavor, belongs to vegetal natural perfume.When using separately, not diarrhea effect, but owing to have antibacterial action preferably, pathogenic entero becteria there is certain inhibitory action.When 1: 8000～1: 16000 concentration, can inhibitory action be arranged to pathogenic fungus; When 1: 2000～1: 8000 concentration, bacillus such as staphylococcus aureus and pneumonia, dysentery (will and low), large intestine, distortion, tuberculosis all there is inhibitory action.And eugenol also has tangible digestion promoting function, and 5% Emulsion can make gastric mucus secretion significantly increase, and acidity does not increase.In medicine of the present invention, we add the eugenol composition, and discovery can significantly strengthen the diarrhea effect of mice, and this may be relevant with the kinetics function of eugenol.
Polyvinylpolypyrrolidone (pvpp) claims polyethylene pyrrole network alkane ketone, polyvidone again, is a kind of high molecular polymer, is used as disintegrating agent and binding agent on the preparation of being everlasting.But meanwhile it also has the effect of very high absorbing toxin, and absorbing toxin optionally.We know because antibiotics attack normal flora causes a large amount of breedings of pathogenic bacteria, show as the secretion of toxin.Pvpp makes intestinal microbial population return to normal poised state after adsorbing these toxin then.The objective of the invention is to prepare a kind of safety, low toxicity, efficient, wide adaptability, cheap, the treatment diarrheal medicine of conveniently taking, carry, transporting.Can effectively dispel pathogen, the protection gastrointestinal mucosa,, promote damaged cytothesis, strengthen the cell humoral immunization, recover a cell and normally absorb and secretory function, make the diarrhoea recovery from illness at short notice.In Guo Yuelin " polyethylene pyrrole network alkane ketone is to the effect of big porker " (Chinese feedstuff 1993.6), mention and studied the absorption of pvpp to mycotoxin; In " vitro " book, also obtained confirmation in as the test of toxin with dyestuff (serge blue and bromjophenol blue); In " vivo " book with vole and optionally bacterial endotoxin do animal research and obtained more directly proof.In this test, wherein 10 voles are by the endotoxin of peritoneal injection 2mg from the extraction of enteritis Salmonella kind in the matched group, and another test group is then accepted 2mg has contacted 3 hours endotoxin residue with the pvpp of 200ml peritoneal injection.The result of death toll (as table 1) has clearly shown the endotoxic ability of pvpp absorption enteritis Salmonella.Use escherichia coli 0.11B4 endotoxin simultaneously, Sai Shi bacillus subtilis endotoxin has all obtained identical conclusion with the test that the poly-polysaccharide of salmonella typhi fat is done.
The table 1 pair endotoxic absorption of enteritis Shan Menshi bacillus
| Group | Mortality rate | ||||
| 0-17 hour | 24 hours | 48 hours | 62 hours | Survived 7 days | |
| Matched group | 6 | 3 | --- | 1 | 0/10 |
| Experimental group | ---- | 1 | 1 | --- | 8/10 |
Because the structure of pvpp itself, it all is neutral on chemistry and biological angle, so pvpp can recover acid-base balance by the function of adsorber acid or alkali, makes the recovery of intestinal pH value normally.What need explanation a bit is exactly that pvpp does not adsorb basic group, but can adsorb the phenols toxin that contains basic group.This effect is found in the dye adsorption test described in " VIREO " book: the pH value of the upper strata stillness of night always turns to neutrality behind the adsorption.
Pharmaceutical composition of the present invention is combined into compound medicine with both, shows tangible diarrhea effect, can protect intestinal mucosa simultaneously.It is concrete following advantage:
1) the present invention is very effective coalition and the adsorbent that multiple molecule comprises toxin.
2) the present invention can combine with the phenols toxin that contains base groups, and when it can adsorber acid or during alkali (two kinds all are present in digestive tract) just present " soda acid both sexes ", therefore can not influence the curative effect effect of antibiotics, can not cause the constipation symptom of taking frequent appearance as other anti-diarrheal; Also can not cause the stool of color exception.
3) be a kind of hydroaropic substance owing to containing pvpp among the present invention, water insoluble, sour, alkali and other solvent, but it very easily expands rapidly in water, wet thing, therefore can in gastric juice, intestinal juice, not dissolve, can not be by gastrointestinal tract barrier must 100% excrete, so the present invention uses as safe as a house, there is not significant side effects.
4) the present invention has good tolerance, and only needs the low dose of effect that just can reach the protection intestinal mucosa, so it is applicable to adult, child and baby.
5) present composition is the product that characteristics and advantage with traditional Chinese medicine combine with the modern medicine technology, have characteristics efficient, quick-acting, that dosage is little, toxic and side effects is little, and it is cheap and easy to get conveniently to take, carry, transport and produce and originate in material, best embodies modernization of Chinese medicine level.
The specific embodiment
Pharmaceutical composition of the present invention is except containing eugenol, polyvidone as the effective ingredient, can also contain one or more pharmaceutically acceptable adjuvants, preferred said composition is a unit dosage form as solid or liquid preparations such as tablet, pill, powder, granule, powder, dry suspension, suspensions.Pharmaceutical composition of the present invention can carry out administration by the known administering mode of one of ordinary skill in the art, and for example oral, rectally are preferably oral administration.Pharmaceutical composition of the present invention and the acceptable inert carrier of oral nontoxic materia medica are combined and are made oral solid formulation.Because eugenol is oily liquids, can adopt the beta-schardinger dextrin-method to carry out enclose, feed intake with the form of clathrate, to have increased stability of drug, guarantee clinical curative effect.With the eugenol beta-cyclodextrin inclusion compound, can make dry suspension.Its weight ratio: eugenol 0.2%-2%, pvpp40%-70%, beta-schardinger dextrin-2-20%, sucrose 20-50%, sodium carboxymethyl cellulose 2%-5%.Also can adopt the operational approach of tradition absorption, directly eugenol is adsorbed in the polyvinylpolypyrrolidone, when guaranteeing curative effect, also can simplify the operation, reduce production costs according to the dosage form of medicine.In another concrete embodiment, this pharmaceutical composition is made powder, its weight ratio is: eugenol 0.2%-2%, pvpp 40%-70%, sodium chloride 5%-20%, mannitol 5-20%, lactose 5-20%; The inventor has only got middle scale in these examples, but this can not constitute limitation of the scope of the invention.
The present invention also provides above-mentioned eugenol, the application of polyvinylpolypyrrolidone (pvpp) in treatment diarrhoea, preferred therapeutic child baby or adult's acute diarrhea or subacute diarrhoea, the acute diarrhea of more preferably treating child and baby.Preferably with reference to pharmaceutical composition of the present invention, also two kinds of compositions can be prepared into the ratio administration of a kind of medicine with reference to ingredient of the present invention respectively, diarrhoea is treated in administration simultaneously.
For the ease of understanding, below we will present invention is described by specific embodiment.It needs to be noted that these describe only exemplary description, do not constitute the restriction of the scope of the invention.According to the argumentation of this description, many modifications of the present invention all are conspicuous concerning one of ordinary skill in the art.
The prescription and the preparation method (beta-cyclodextrin inclusion compound) of embodiment 1, poly-dimension phenol dry suspension
1, prescription scope:
Eugenol 10g
Beta-schardinger dextrin-50g
Polyvinylpolypyrrolidone 520g
Sucrose 350g
Sodium carboxymethyl cellulose 60g
Carboxymethyl starch sodium 10g
The 5%pvp ethanol solution is an amount of
Make 1000g
2, preparation method
(1) eugenol in will writing out a prescription and polyvinylpolypyrrolidone are crossed 100 mesh sieves respectively, and be standby.
Adjuvant in the prescription is crossed 100 mesh sieves respectively.
(2) beta-schardinger dextrin-that takes by weighing recipe quantity adds 200ml distilled water mix homogeneously, is heated to dissolving fully, places room temperature, adds eugenol and mixes, and shake well stirred after 3 hours, puts (2-5 ℃) refrigerator and cooled Tibetan and spends the night sucking filtration.The a small amount of distilled water wash of clathrate is drained; The a spot of ether washing of reuse is drained.40 ℃ of following vacuum decompression dryings, non-oxidation two phosphorus are as water absorbing agent, and drying 3 hours promptly gets pulverous clathrate, and is standby.
(3) with adjuvant mix homogeneously such as eugenol clathrate, polyvinylpolypyrrolidone, carboxymethyl starch sodium, sodium carboxymethyl cellulose and sucrose, add the 5%pvp ethanol solution and make soft material, granulate with 20 mesh sieves, in 50-60 ℃ of aeration-drying 2 hours, 18 mesh sieve granulate, packing promptly.
The prescription and the preparation method of embodiment 2 poly-dimension phenol powders
1, prescription compositing range
Eugenol 1.0%
Polyvinylpolypyrrolidone 50%
Sodium chloride 15%
Lactose 19%
Mannitol 15%
2, preparation method:
(1) the 500g polyvinylpolypyrrolidone is ground into impalpable powder, standby;
150g sodium chloride, 150g mannitol, 190g lactose are ground into fine powder, cross the 100-120 mesh sieve, standby;
(2) with (with the mixer of spraying apparatus) in the polyvinylpolypyrrolidone impalpable powder Place shape blender, spray into the 10g eugenol.Under airtight situation, stir, placed one day, to guarantee that eugenol is adsorbed fully;
(3) in this blender, add other adjuvant, mixing sieves.
(4) packing promptly.
The prescription and the preparation method of embodiment 3 poly-dimension phenol dispersible tablets
1, prescription:
Eugenol 20g
Beta-schardinger dextrin-100g
Polyvinylpolypyrrolidone 600g
Lactose 300g
Microcrystalline Cellulose 100g
Magnesium stearate is an amount of
The 3%pvp alcoholic solution is an amount of
Make 1000
2, preparation method
(1) polyvinylpolypyrrolidone in will writing out a prescription (recipe quantity 1/2) is crossed 100 mesh sieves, and is standby;
With the adjuvant pulverize separately except that magnesium stearate in the prescription, cross 100 mesh sieves, standby;
(2) take by weighing the beta-schardinger dextrin-of recipe quantity, place mortar, add a certain amount of distilled water, grind evenly, eugenol (be made into dehydrated alcohol 50% the concentration) alcoholic solution that slowly adds recipe quantity, continuously grinding place 0-4 ℃ refrigerator and cooled to hide to pasty state.Sucking filtration with a spot of ether washing, is drained.40 ℃ of following vacuum decompression dryings, phosphorus pentoxide are as water absorbing agent, and drying 3 hours promptly gets pulverous clathrate, and is standby.
(3) clathrate and the above-mentioned adjuvant mix homogeneously after will sieving is that binding agent is made soft material with the clathrate and the adjuvant of mix homogeneously with the 3%pvp alcoholic solution, granulates 40-50 ℃ of drying with 20 mesh sieves;
(4) with dried granule with 18 mesh sieve granulate;
(5) with second half polyvinylpolypyrrolidone and magnesium stearate and above-mentioned granule mix homogeneously of recipe quantity, tabletting, the bag film-coat, promptly.
Experimental data:
The invention provides the application in treatment diarrhoea in this pharmaceutical composition, the acute diarrhea that is particularly useful for treating adult and child.For the reasonability of the prescription of assessing medicine of the present invention, the inventor is by carried out the side's of tearing open analysis on the diarrhea of mouse model, for later clinical practice provides theoretical foundation.
The inventor with the dry suspension of this medicine as being subjected to the reagent thing, with the dosage of high dose (0.2g/kg) as full side, all the other each prescriptions are all according to ratio (the prescription in example 1 of each single medicine at Quan Fangzhong, contain eugenol 1g, pvpp 52g in every 100g dry suspension) calculate corresponding dosage, result's (seeing Table 2)
The comparison of full side of table 2 and the effect of the anti-mice Oleum Ricini of single medicament composing prescription diarrhoea
| Group | Number of animals (n) | Muck number (n) (X ± SD) |
| Matched group | 12 | 8.5±1.5 |
| Full side group | 12 | 4.0±1.9 ** |
| Eugenol | 12 | 7.1±2.1 |
| pvpp | 12 | 6.0+1.8 ** |
Compare with matched group
*P＜0.01
The result shows in this medicine that in the single medicament composing prescription, eugenol does not show tangible diarrhea effect, and pvpp presents the diarrhea effect.The analysis showed that through the side of tearing open full side group is compared with the diarrhea effect of each prescription, the effect that still shows full side is best.
The inventor has also made a large amount of research work to compound formulation main pharmacodynamics of the present invention, has estimated the main pharmacological of medicine of the present invention, provides theoretical foundation for clinical practice once more.
1, experiment material:
1. be subjected to the reagent thing: dry suspension of the present invention is provided lot number by Xi'an Xintong Medicine Research Co., Ltd.: 060512, be mixed with desired concn with distilled water before the experiment.
2. control drug: dioctahedral smectite (Smecta), produce lot number: L2LLC by France beneficial Pu Shengbofu pharmaceutical factory.Be configured to desired concn with distilled water before the experiment.
3. other reagent: medical Oleum Ricini, Wenshui County Oleum Ricini factory provides by Shanxi
4. animal: Kunming mouse,
♀, body weight 18-22g, the certification of fitness: the moving card of Shan doctor word 08-004 number, the laboratory room temperature is 20 ± 2 ℃, relative humidity 60-70%, lamp.
2, method and result
(1) dry suspension of the present invention influences Oleum Ricini induced mice diarrheal
60 of kunming mices, male and female half and half, body weight 18-22g is divided into 5 groups at random, be respectively matched group, positive drug smecta group (0.2g/kg) and dry suspension height of the present invention (0.2g/kg), in (0.1g/kg) and low dose group (0.05g/kg), difference per os gastric infusion secondary on the same day, twice dosing interval 4 hours, the next morning is administered once, after the administration 1 hour, irritate stomach and only give Oleum Ricini 0.3ml/, immediately animal is put into the open special wire mesh cage in bottom.One in every cage, filter paper is spread in the bottom, the muck that releases with mice (lapaxis periphery have watermark to moisten) number is an index, observe and record 6h in respectively organize the muck sum.Result's (seeing Table 3)
Table 3 dry suspension of the present invention is to the influence of Oleum Ricini induced mice diarrhoea model
| Group | Dosage (/kg) | Number of animals (n) | Muck number (n) (X+SD) |
| Dosage group in the heavy dose of group of the matched group dioctahedral smectite dry suspension of the present invention dry suspension of the present invention | 0.2g 0.2g 0.1g | 12 12 12 12 | 7.3±2.1 3.2±1.6 **3.7±1.6 **4.2+1.5 ** |
| Dry suspension low dose group of the present invention | 0.05g | 12 | 5.9±1.9 |
Compare with matched group
*P＜0.01
(2) dry suspension of the present invention is to the influence of mice intestine movement function
Kunming mouse, male and female half and half, 18-22g is divided into 5 groups at random, is respectively matched group, positive drug smecta group (0.2g/kg), poly-dimension phenol dry suspension height (0.2g/kg), in (0.1g/kg) and low dose group (0.05g/kg), the per os gastric infusion was administered twice in first day, 4 hours at interval, administration on the secondth only gavages Oleum Ricini 3ml/ simultaneously, behind the 30min, irritates stomach and gives 5% charcoal end (with the preparation of 1% gelatin), every 0.4ml/ only, animal is put to death in dislocation of cervical vertebra behind 30min, dissects immediately and takes out small intestinal, measures distance from pylorus to blind portion and pylorus advance the forward position to the charcoal end distance, and calculate the propelling percentage rate, the results are shown in Table 4
Table 4 dry suspension of the present invention is to the influence of mouse small intestine motor function
| Group | Dosage (/kg) | Number of animals (n) | The charcoal end advances percentage rate (%) (X+SD) |
| Dosage group in the heavy dose of group of the matched group dioctahedral smectite dry suspension of the present invention dry suspension of the present invention | 0.2g 0.2g 0.1g | 12 12 12 12 | 82.3±9.1 54.8±8.9 ** 60.3+7.2 ** 61.1+8.3 ** |
| Dry suspension low dose group of the present invention | 0.05g | 12 | 70.7±7.7 |
Compare with matched group
*P＜0.01
On the diarrhea of mouse animal model due to the Oleum Ricini, show tangible diarrhea effect by above result dry suspension high dose group of the present invention as can be seen and middle dosage group, and suppress the mouse small intestine ahead running that causes by Oleum Ricini, the result similar to dioctahedral smectite positive drug group (
*P＜0.01=)
Claims (6)
1, a kind of treatment diarrheal pharmaceutical composition, it comprises eugenol, polyvinylpolypyrrolidone and acceptable accessories.
2, treatment diarrheal pharmaceutical composition according to claim 1, wherein the content of eugenol is: 0.05-5%, be preferably 0.2-2%, 0.5-1.5% more preferably, the content of polyvinylpolypyrrolidone is: 20-80% is preferably 40-70%, 50-60% more preferably, the content of acceptable accessories is: 20-80% is preferably 28-58%, more preferably 38.5-48.5%.
3, treatment diarrheal pharmaceutical composition according to claim 1 and 2, described acceptable accessories is selected from one or more in sodium chloride, mannitol, lactose, sucrose, sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, carboxymethyl starch sodium, 3%-5%pvp ethanol solution, sodium chloride, polyvinylpolypyrrolidone, microcrystalline Cellulose or the magnesium stearate.
4, treatment diarrheal pharmaceutical composition according to claim 3 is made dry suspension, suspension, powder, granule, tablet oral administration solid or liquid preparation.
5, in the treatment diarrheal pharmaceutical composition according to claim 4, when described pharmaceutical composition was made dry suspension, suspension, eugenol was the eugenol that carries out enclose with beta-schardinger dextrin-.
6, in the treatment diarrheal pharmaceutical composition according to claim 5, inclusion method wherein adopts recrystallization method or polishing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100178409A CN101062021B (en) | 2007-05-14 | 2007-05-14 | Diarrhea treating medical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100178409A CN101062021B (en) | 2007-05-14 | 2007-05-14 | Diarrhea treating medical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101062021A true CN101062021A (en) | 2007-10-31 |
| CN101062021B CN101062021B (en) | 2011-06-01 |
Family
ID=38963442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100178409A Active CN101062021B (en) | 2007-05-14 | 2007-05-14 | Diarrhea treating medical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101062021B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885851A (en) * | 2012-10-12 | 2013-01-23 | 西安新通药物研究有限公司 | Drug for treating diarrhea |
| CN103316191A (en) * | 2013-07-11 | 2013-09-25 | 石强 | Natural medicine extract |
| CN106962601A (en) * | 2017-02-21 | 2017-07-21 | 北京金道欣生物技术有限公司 | A kind of nanometer is coated the fragrant phenol of wild marjoram and its application |
-
2007
- 2007-05-14 CN CN2007100178409A patent/CN101062021B/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885851A (en) * | 2012-10-12 | 2013-01-23 | 西安新通药物研究有限公司 | Drug for treating diarrhea |
| CN103316191A (en) * | 2013-07-11 | 2013-09-25 | 石强 | Natural medicine extract |
| CN106962601A (en) * | 2017-02-21 | 2017-07-21 | 北京金道欣生物技术有限公司 | A kind of nanometer is coated the fragrant phenol of wild marjoram and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101062021B (en) | 2011-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101869611A (en) | Admixture capable of repelling chicken coccidiosis and stopping dysentery and preparation method thereof | |
| CN101062021B (en) | Diarrhea treating medical composition | |
| CN103127198B (en) | Combined drug for treating piglet's yellow-white dysentery | |
| CN103463217B (en) | A kind of treat enteritis and dysentery extract, containing its preparation and its preparation method and application | |
| CN101244164A (en) | Medicament for preventing and treating hydropsy of pigling | |
| CN100337645C (en) | Medicine composition for treating acute pharyngitis and its prepn | |
| CN1810265A (en) | Total sennoside extract for treating constipation and its extraction process | |
| CN102488767B (en) | Compound composition for treating bacterial diarrhoea of livestock and poultry | |
| CN1267110C (en) | Elsholizia extract prepn and its quality control method and new use | |
| CN1220496C (en) | Bougie for treating virus hepatitis and preparing method thereof | |
| CN100344319C (en) | Chinese medicine composition for treating urogenital system disease and its preparing method and use | |
| CN1686091A (en) | Composition of aiphenyl hepatanone compound and its use | |
| CN1660350A (en) | Combination of medication of containing medicinal rhubarb and activated carbon or carbo medicinalis | |
| CN1853708A (en) | Use of Galangal fruit and its extract in pharmacy | |
| CN103861007A (en) | Chinese herbal medicine compound preparation for treating diarrhea of chicken | |
| CN1318036C (en) | Calcium aluminium suspension | |
| AU2021103716A4 (en) | An Enema Pharmaceutical Composition For Treating Diarrhea Of Piglet | |
| CN1255124C (en) | Application of Psoralca corylifolia in anti-infection of helicobacter pyloric and treating relative diseases | |
| CN1689579A (en) | Application of burdock glycoside or its aglycon in preparation of medicine for treating diabetes or its complications | |
| CN100473392C (en) | Compound clore basil preparation | |
| CN109908281B (en) | Livestock detoxification composition and application thereof | |
| CN1660349A (en) | Combination of medication by using beartyberry and dragon's blood resin as combination of activities | |
| CN1561997A (en) | Medicinal composition having anti-inflammation and anti-infection function | |
| CN116570664A (en) | Traditional Chinese medicine composition for treating chicken leg arthritis and application thereof | |
| CN1252279A (en) | Soluble heme and its preparation process and hematic composite with it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: XI'AN XINTONG MEDICINE RESEARCH CO., LTD. Free format text: FORMER OWNER: ZHANG DENGKE Effective date: 20111009 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710075 XI'AN, SHAANXI PROVINCE TO: 710077 XI'AN, SHAANXI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20111009 Address after: 710077 C, block 2, room 69, pioneer research and Development Park, 205 Kam Yip Road, hi tech Zone, Shaanxi, Xi'an Patentee after: Xi'an Xintong Pharmaceutical Research Co., Ltd. Address before: 710075, No. 12, C District, 69 Kam Yip Road, hi tech Zone, Shaanxi, Xi'an Patentee before: Zhang Dengke |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Jiangsu Runbang Pharmaceutical Co., Ltd. Assignor: Xi'an Xintong Pharmaceutical Research Co., Ltd. Contract record no.: 2011320001162 Denomination of invention: Medicine composition for treating diarrhea Granted publication date: 20110601 License type: Exclusive License Open date: 20071031 Record date: 20111122 |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 710077 Room 205, 2nd Floor, Block C, Venture Development Park, 69 Jinye Road, Xi'an High-tech Zone, Shaanxi Province Patentee after: Xi'an Xintong Pharmaceutical Research Co.,Ltd. Address before: 710077 Room 205, 2nd Floor, Block C, Venture Development Park, 69 Jinye Road, Xi'an High-tech Zone, Shaanxi Province Patentee before: XI'AN XINTONG PHARMACY RESEARCH Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |